People

Noa Krawczyk
Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public Health
BA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment
BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery.
Projects
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications

Recent

Krawczyk N, Rivera BD, Basaraba C, Corbeil T, Allen B, Schultebraucks K, Henry BF, Pincus HA, Levin FR, Martinez D (2022).
COVID-19 complications among patients with opioid use disorder: A retrospective cohort study across five major NYC hospital systems
Addiction [Epub 2022 Dec 2]. doi: 10.1111/add.16105.

Krawczyk N, Maniates H, Hulsey E, Smith JS, DiDomenico E, Stuart EA, Saloner B, Bandara S (2022).
Shifting medication treatment practices in the COVID-19 pandemic: A statewide survey of Pennsylvania opioid treatment programs
Journal of Addiction Medicine, 16 (6), 645-652. doi: 10.1097/ADM.0000000000000981. PMCID: PMC9653109.

Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerda M (2022).
Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019
International Journal of Drug Policy, 110, 103786. doi: 10.1016/j.drugpo.2022.103786.

Bunting AM, Krawczyk N, Choo TH, Pavlicova M, McNeely J, Tofighi B, Rotrosen J, Nunes E, Lee JD (2022).
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes
Journal of Substance Abuse Treatment, 143, 108830. doi: 10.1016/j.jsat.2022.108830.

Lim S, Cherian T, Katyal M,, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, MacDonald R, Lee JD (2022).
Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-2017
Addiction [Epub 2022 Oct 28]. doi: 10.1111/add.16071.


Notable

Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019).
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.

Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.

Dr. Krawczyk's MyBibliography Profile
Selected Press